Rebecca practices general corporate and securities law. She represents private and public companies in a wide range of industries and at all stages of their life cycle, as well as investors and underwriters.
Olema Pharmaceuticals Combined Financing for Up to $180 Million
September 5, 2023
Cooley advised Olema Pharmaceuticals, Inc. on its private placement of approximately $130 million in common stock and a senior secured credit facility with an aggregate principal amount of up to $50 million. Jodie Bourdet and Julia Boesch led the team advising on the private placement, which included Julia Gage and Rebecca Siegel. Addison Pierce led the team advising on the credit facility, which included Margaret Barreto. Olema, whose securities trade on the Nasdaq Global Market under the symbol “OLMA,” is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers.
ACELYRIN Announces Pricing of Upsized Initial Public Offering
May 15, 2023
Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.